Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4473 |
Ibiglustat
Venglustat,SAR402671,GZ402671 |
Transferase | Metabolism |
Ibiglustat (GZ402671) 是一种可透过血脑屏障的、具有口服活性的葡萄糖神经酰胺合成酶(GCS)抑制剂。它可用于戈谢病 3 型、法布瑞氏症、与 GBA 突变相关的帕金森病、GM2 神经节苷脂病和常染色体显性多囊肾病的研究。 | |||
T11599 |
Ibiglustat (L-Malic acid)
Ibiglustat L-Malic acid,GZ402671 (L-Malic acid),Venglustat (L-Malic acid),SAR402671 (L-Malic acid) |
Transferase | Metabolism |
Ibiglustat (L-Malic acid) (Ibiglustat L-Malic acid) 是一种选择性的、脑渗透性的和别构的葡萄糖神经酰胺合酶抑制剂。 Ibiglustat (L-Malic acid) 可用于关于 PD 帕金森病、法布里和戈谢氏 SRT 的研究。 | |||
T39105 |
Ibiglustat succinate
GZ402671succinate,Venglustat succinate,Ibiglustat succinate,SAR402671succinate |
||
Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant inhibitor of glucosylceramide synthase (GCS). It is utilized in the investigation of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease. | |||
T70347 |
Ibiglustat hydrochloride
|
||
Ibiglustat hydrochloride is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. | |||
T70346 |
TOP1362
|
||
TOP1362 is a Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders. TOP1362 strongly inhibited the kinase targets p38α, Syk, Src, and Lck, blocked the rise in p38α expression in hyperosmolar Chang cells, and potently reduced inflammatory cytokine release in cellular models of innate and adaptive immunities. In the EIU model, TOP1362 dose-dependently attenuated the LPS-induced rise in inflammatory cell infiltration and o... |